The American drug regulator said yesterday it would be reviewing the safety of two AstraZeneca treatments after studies raised fears they could increase the risk of heart attacks. The drugs, for stomach ulcers, are Prilosec and Nexium - its top seller with sales of $5bn (£2.5bn) a year.
